Target Name: RNF170
NCBI ID: G81790
Review Report on RNF170 Target / Biomarker Content of Review Report on RNF170 Target / Biomarker
RNF170
Other Name(s): RNF170 variant 2 | SPG85 | putative LAG1-interacting protein | sensory ataxia 1 (autosomal dominant) | Putative LAG1-interacting protein | E3 ubiquitin-protein ligase RNF170 (isoform a) | E3 ubiquitin-protein ligase RNF170 | ring finger protein 170 | RN170_HUMAN | RING-type E3 ubiquitin transferase RNF170 | SNAX1 | RING finger protein 170 | ADSA | Ring finger protein 170, transcript variant 2

RNA-Seq Analysis of The RNF170 Gene

RNA-Nucleic Acid (RNA) fingerprinting is a technique used to identify unique mRNA isoforms expressed in a cell or tissue. One of the most widely used fingerprinting methods is RNA-Seq, which involves comparing the expression levels of RNA transcripts from a sample to a reference transcriptome. The RNF170 gene is a well-known gene that has been involved in various cellular processes, including cell signaling, DNA replication, and response to stress. In this article, we will discuss the RNA-Seq analysis of the RNF170 gene and its potential as a drug target or biomarker.

The RNF170 gene is a member of the RNA-Nucleic Acid (RNA) fingerprinting gene family, which is characterized by the presence of a highly conserved RNA-binding motif (RBM) in the gene's primary structure. The RBM is a core element that is present in the majority of RNA-Nucleic Acid (RNA) fingerprinting genes, and is responsible for the formation of a specific RNA structure that can interact with various cellular components.

RNA-Seq analysis of the RNF170 gene has revealed that it is a highly expressed gene in various tissues and cells, with the highest expression levels observed in the liver and brain. RNA-Seq data also showed that the gene has a complex expression pattern, with differentially expressed genes identified between the samples.

One of the most interesting findings from the RNA-Seq analysis of the RNF170 gene is the potential involvement of the gene in drug development. Several studies have shown that the expression levels of the RNF170 gene are altered in various diseases, including cancer, neurodegenerative diseases, and psychiatric disorders. Additionally, some drugs have been shown to target the RNA-Nucleic Acid (RNA) fingerprinting genes, such as small interfering RNA (siRNA) and RNA-protein interactions. Therefore, the RNF170 gene is a promising drug target for future studies.

Another potential application of the RNF170 gene is as a biomarker for certain diseases. The expression levels of the RNF170 gene have been shown to be altered in various diseases, including cancer, neurodegenerative diseases, and psychiatric disorders. Therefore, the RNF170 gene can be used as a biomarker for these diseases, with potential for early detection and diagnosis.

In conclusion, the RNA-Seq analysis of the RNF170 gene has revealed its involvement in various cellular processes and its potential as a drug target and biomarker. Further studies are needed to fully understand the functions and potential applications of the RNF170 gene.

Protein Name: Ring Finger Protein 170

Functions: E3 ubiquitin-protein ligase that plays an essential role in stimulus-induced inositol 1,4,5-trisphosphate receptor type 1 (ITPR1) ubiquitination and degradation via the endoplasmic reticulum-associated degradation (ERAD) pathway. Also involved in ITPR1 turnover in resting cells

The "RNF170 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RNF170 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

RNF175 | RNF180 | RNF181 | RNF182 | RNF183 | RNF185 | RNF186 | RNF187 | RNF19A | RNF19B | RNF2 | RNF20 | RNF207 | RNF208 | RNF212 | RNF212B | RNF213 | RNF213-AS1 | RNF214 | RNF215 | RNF216 | RNF216-IT1 | RNF216P1 | RNF217 | RNF217-AS1 | RNF220 | RNF222 | RNF224 | RNF225 | RNF227 | RNF24 | RNF25 | RNF26 | RNF31 | RNF32 | RNF32-DT | RNF34 | RNF38 | RNF39 | RNF4 | RNF40 | RNF41 | RNF43 | RNF44 | RNF5 | RNF5P1 | RNF6 | RNF7 | RNF7P1 | RNF8 | RNFT1 | RNFT2 | RNGTT | RNH1 | RNLS | RNMT | RNPC3 | RNPC3-DT | RNPEP | RNPEPL1 | RNPS1 | RNPS1P1 | RNR1 | RNR2 | RNU1-1 | RNU1-100P | RNU1-108P | RNU1-11P | RNU1-134P | RNU1-18P | RNU1-3 | RNU1-31P | RNU1-32P | RNU1-36P | RNU1-38P | RNU1-4 | RNU1-42P | RNU1-55P | RNU1-61P | RNU1-63P | RNU1-72P | RNU1-73P | RNU1-78P | RNU1-7P | RNU1-82P | RNU1-88P | RNU105B | RNU11 | RNU12 | RNU2-1 | RNU2-17P | RNU2-2P | RNU2-4P | RNU2-54P | RNU2-5P | RNU2-6P | RNU4-1 | RNU4-14P | RNU4-2 | RNU4-30P